Decomposition-driven biomarker identification enhances non-invasive early cancer detection
Better methods for identifying cancer DNA markers in blood may improve early detection and patient stratification.
Accurate marker selection in cell-free DNA (cfDNA) is essential for non-invasive early cancer detection, yet conventional approaches based on bulk tissue data often yield markers with limited efficacy in blood-based assays, due to the sparse and heterogeneous nature of tumor-derived cfDNA released into the bloodstream during early tumorigenesis. Together, our framework offers a robust and scalable solution to improve biomarker identification for early cancer detection and patient stratification.
What the study was
- Study design
- Journal Article
- Population
- Accurate marker selection in cell-free DNA (cfDNA) is essential for non-invasive early cancer detect
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- iScience
Why it surfaced
Primary method is liquid biopsy/ctDNA/cfDNA for cancer detection; moderate relevance to watchlist
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.